Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders (Q35155918)

6 August 2017

Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders (English)

1 reference

6 August 2017

1 reference

Frank Gianfrancesco

1

1 reference

6 August 2017

Amy Grogg

2

1 reference

6 August 2017

Ramy Mahmoud

3

1 reference

6 August 2017

Ruey Hua Wang

4

1 reference

6 August 2017

Dennis Meletiche

5

1 reference

6 August 2017

1 April 2003

1 reference

6 August 2017

Clinical Therapeutics

1 reference

6 August 2017

25

1 reference

6 August 2017

4

1 reference

6 August 2017

1150-1171

1 reference

Prevalence and correlates of diabetes in national schizophrenia samples.

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Prevalence of diabetes in a manic-depressive population

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Prevalence of depression in adults with diabetes. An epidemiological evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

The prevalence of comorbid depression in adults with diabetes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

White matter signal abnormalities in normal individuals: correlation with carotid ultrasonography, cerebral blood flow measurements, and cerebrovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Brain abnormalities demonstrated by magnetic resonance imaging in adult IDDM patients with and without a history of recurrent severe hypoglycemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Magnetic resonance imaging signal hyperintensities in the deep and subcortical white matter. A comparative study between stroke patients and normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Subcortical signal hyperintensities in bipolar patients detected by MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

T2 hyperintensities in bipolar disorder: magnetic resonance imaging comparison and literature meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

White matter hyperintensity on magnetic resonance imaging: clinical and neuroanatomic correlates in the depressed elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Subcortical hyperintensities on magnetic resonance imaging: Clinical correlates and prognostic significance in patients with severe depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Elevated sorbitol concentration in the cerebrospinal fluid of patients with mood disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Diabetic ketoacidosis with olanzapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Hyperglycemia and olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Clozapine-induced diabetic ketoacidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Diabetic ketoacidosis associated with clozapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Hyperglycemia associated with olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Novel antipsychotics and new onset diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Diabetic ketoacidosis and clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Clozapine and associated diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Diabetic ketoacidosis from clozapine and lithium cotreatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Ketoacidosis as a side-effect of clozapine: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Diabetic ketoacidosis associated with clozapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Severe hyperglycemia associated with high doses of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Olanzapine-induced glucose dysregulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Olanzapine-lnduced hyperglycemic nonketonic coma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Diabetic ketoacidosis associated with risperidone treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Risperidone-associated new-onset diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Resolution of hyperglycemia on risperidone discontinuation: a case report.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Schizophrenia and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Quetiapine-associated hyperglycemia and hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Atypical antipsychotics and hyperglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

New onset diabetes and atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Weight changes during clozapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Olanzapine-Induced Weight Gain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Differential effect of clozapine on weight: a controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Weight gain among schizophrenic patients treated with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Clozapine-induced weight gain: prevalence and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Weight gain associated with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Studies on the Mechanism of Pentobarbital-Induced Glucose Intolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Affective disorders, diabetes mellitus and lithium

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. The Consensus Study Group on Risperidone Dosing

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980073-5

7 January 2021

10.1016/S0149-2918(03)80073-5

Identifiers

DOI

1 reference

6 August 2017

1 reference